他汀治疗与2型糖尿病多发性神经病变风险:丹麦队列研究
该丹麦全国队列研究纳入2002-2016年新发2型糖尿病患者,比较新使用、既往使用他汀者与未使用者发生糖尿病多发性神经病变(DPN)的风险。结果显示,新使用者DPN风险比未使用者略高(aHR 1.05,95%CI 0.98-1.11),既往使用者为0.97(0.91-1.04);新使用者第一年风险略增(1.31,1.12-1.53),2年后消失。结论认为他汀治疗不太可能增加或减轻DPN风险,但不能排除小的急性危害。
要点
- 他汀新使用者DPN风险与未使用者相似(aHR 1.05,95%CI 0.98-1.11)。
- 他汀既往使用者DPN风险与未使用者相似(aHR 0.97,95%CI 0.91-1.04)。
- 新使用者第一年DPN风险略增(aHR 1.31,95%CI 1.12-1.53),2年后消失。
核心结论
- 他汀治疗不太可能增加或减轻2型糖尿病患者DPN风险,但不能排除小的急性危害。
研究设计与样本
- 丹麦全国队列研究,纳入2002-2016年新发2型糖尿病患者,分为他汀新使用者、既往使用者和未使用者,随访至出现DPN。
主要发现
- 队列包括新使用者59,255例(23%)、既往使用者75,528例(29%)、未使用者124,842例(48%),中位随访6.2年(IQR 3.4-9.6)。
- DPN发病率(每1000人年):新使用者4.0(95%CI 3.8-4.2),既往使用者3.8(3.6-3.9),未使用者3.8(3.7-4.0)。
- 与未使用者相比,新使用者aHR 1.05(0.98-1.11),既往使用者aHR 0.97(0.91-1.04)。
- 新使用者第一年DPN风险aHR 1.31(1.12-1.53),随访>2年后消失。
- 在意向治疗分析和倾向评分匹配分析中结果相似,额外调整治疗前血脂水平后结果亦相似。
临床怎么用
- 对于2型糖尿病患者,他汀治疗无需因担心DPN风险而停用,但起始治疗第一年应关注神经病变症状。
局限性
- 观察性研究可能存在残余混杂,不能排除小的急性危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Statins may reduce the risk of diabetic polyneuropathy (DPN) as a result of lipid-lowering and anti-inflammatory effects, but statins have also been associated with neurotoxicity. We examined whether statin therapy affects the risk of DPN. RESEARCH DESIGN AND METHODS: We identified all Danish patients with incident type 2 diabetes during 2002-2016. New users initiated statins between 180 days before and 180 days after their first diabetes record, while prevalent users had initiated statins before that period. Patients were followed for incident DPN using validated hospital diagnosis codes, starting 180 days after their first diabetes record. Cox proportional hazard analysis was used to compute adjusted hazard ratios (aHRs) for DPN. RESULTS: The study cohort comprised 59,255 (23%) new users, 75,528 (29%) prevalent users, and 124,842 (48%) nonusers; median follow-up time was 6.2 years (interquartile range 3.4-9.6). The incidence rate of DPN events per 1,000 person-years was similar in new users (4.0 [95% CI 3.8-4.2]), prevalent users (3.8 [3.6-3.9]), and nonusers (3.8 [3.7-4.0]). The aHR for DPN was 1.05 (0.98-1.11) in new users and 0.97 (0.91-1.04) in prevalent users compared with statin nonusers. New users had a slightly increased DPN risk during the first year (1.31 [1.12-1.53]), which vanished after >2 years of follow-up. Findings were similar in on-treatment and propensity score-matched analyses and with additional adjustment for pretreatment blood lipid levels. CONCLUSIONS: Statin therapy is unlikely to increase or mitigate DPN risk in patients with type 2 diabetes, although a small acute risk of harm cannot be excluded.
引用
- Kristensen FP, Christensen DH, Callaghan BC, et al. Statin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study. Diabetes Care. 2020. PMID: 32998990. doi:10.2337/dc20-1004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。